Daiichi Sankyo receives approval for the use of Inavir® to prevent influenza
Posted: 20 December 2013 | | No comments yet
Inavir® is a long-acting neuraminidase inhibitor developed by Daiichi Sankyo which is manufactured in Japan…
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), announced today that it received approval in Japan to market Inavir® Dry Powder Inhaler 20mg (generic name: Laninamivir Octanoate Hydrate) for the prevention of influenza in both adults and children.
Inavir® is a long-acting neuraminidase inhibitor developed by Daiichi Sankyo which is manufactured in Japan. The drug was originally launched in Japan for treatment of influenza A and B in October 2010.
Daiichi Sankyo has great expectations for the additional influenza prevention indication for Inavir®, which will provide an additional option for the public to protect themselves against the influenza virus and allow Daiichi Sankyo to further contribute to the health of society.
